CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of anti-cluster of differentiation
(CD)47 monoclonal antibody Hu5F9-G4 in treating patients with haematological malignancies
including acute myeloid leukemia that has returned after a period of improvement (relapsed)
or has not responded to previous treatment (refractory), or high risk myelodysplastic
syndrome. Monoclonal antibodies, such as anti-CD47 monoclonal antibody Hu5F9-G4, block cancer
growth in different ways by targeting certain cells.
Phase:
Phase 1
Details
Lead Sponsor:
Forty Seven, Inc. Gilead Sciences
Collaborator:
California Institute for Regenerative Medicine (CIRM)